| Literature DB >> 28148680 |
Sun Eun Lee1, Christine P Stewart2, Kerry J Schulze3, Robert N Cole4, Lee S-F Wu3, James D Yager5, John D Groopman5, Subarna K Khatry6, Ramesh Kant Adhikari7, Parul Christian3, Keith P West3.
Abstract
Background: Malnutrition affects body growth, size, and composition of children. Yet, few functional biomarkers are known to be associated with childhood morphology.Objective: This cross-sectional study examined associations of anthropometric indicators of height, musculature, and fat mass with plasma proteins by using proteomics in a population cohort of school-aged Nepalese children.Entities:
Keywords: Nepal; anthropometry; children; insulin-like growth factor I; insulin-like growth factor–binding proteins; mass spectrometry; plasma proteome
Mesh:
Substances:
Year: 2017 PMID: 28148680 PMCID: PMC5320403 DOI: 10.3945/jn.116.243014
Source DB: PubMed Journal: J Nutr ISSN: 0022-3166 Impact factor: 4.798
FIGURE 1Venn diagram of the number of plasma proteins associated with height-for-age, BMI-for-age, and weight-for-age z scores and arm muscle area in 6- to 8-y-old Nepalese children (q < 0.05). Note: Proteins associated with midupper arm circumference (n = 14), comprising a subset of those associated with arm muscle area, are underlined rather than shown separately. Plasma proteins are indicated as their Human Genome Organization gene symbols. Superscript plus (+) and minus (−) signs indicate positive and negative associations, respectively. AFM, afamin; ANTXR1, anthrax toxin receptor 1; APMAP, adipocyte plasma membrane–associated protein; APOL1, apolipoprotein L1; ATRN, attractin; CCL14, chemokine (C-C motif) ligand 14; CDH5, cadherin 5; CD93, CD93 antigen; CFD, complement factor D; CHGA, chromogranin A; CLEC3B, tetranectin; CNDP1, carnosinase 1; COL6A1, collagen VI, α1; COL6A3, collagen VI, α3; COMP, cartilage oligomeric matrix protein; CTSD, cathepsin D; ENG, endoglin; FAP, fibroblast activation protein; GP5, platelet glycoprotein V; HCF2, heparin cofactor II; HPX, hemopexin; HSPG2, perlecan; IGFALS, insulin-like growth factor, acid labile subunit; IGFBP, insulin like-growth factor–binding protein; IGF1, insulin-like growth factor I; MASP2, mannan-binding lectin serine protease 2; MYLK, myosin light-chain kinase; NRP1, neuropilin 1; OLFM, noelin; PEDF, pigment epithelium-derived factor; PGD, phosphogluconate dehydrogenase; STON2, stonin-2; S100A12, protein S100-A12; THBS4, thrombospondin 4; THNSL1, threonine synthase–like 1; TXN, thioredoxin; VASN, vasorin.
Plasma proteins positively and negatively associated with HAZ in 6- to 8-y-old Nepalese children (q < 0.05)
| Protein (gene symbol) | Change in HAZ | Accession | Molecular function or biological process | |||
| Positive associations | ||||||
| IGF-binding protein, acid labile subunit ( | 498 | 0.80 (0.65, 0.95) | 0.30 | 1.91 × 10−23 | 4826772 | IGF binding |
| IGF-binding protein 3 ( | 498 | 0.59 (0.45, 0.74) | 0.23 | 4.13 × 10−13 | 62243068 | IGF binding |
| Afamin ( | 498 | 0.42 (0.22, 0.62) | 0.15 | 0.0082 | 4501987 | Vitamin E transport |
| IGF I ( | 172 | 0.31 (0.15, 0.46) | 0.09 | 0.0128 | 163659901 | Growth factor |
| Tetranectin ( | 498 | 0.55 (0.26, 0.83) | 0.14 | 0.0218 | 156627579 | Bone matrix |
| Apolipoprotein L1 ( | 498 | 0.32 (0.15, 0.5) | 0.14 | 0.0282 | 211938442 | Lipid transport |
| Carnosinase 1 ( | 498 | 0.17 (0.08, 0.27) | 0.14 | 0.0401 | 21071039 | Carnosine hydrolase |
| Vasorin ( | 498 | 0.39 (0.17, 0.62) | 0.14 | 0.0495 | 88702793 | Vasculogenesis |
| Negative associations | ||||||
| Protein S100-A12 ( | 375 | −0.23 (−0.34, −0.13) | 0.10 | 0.0045 | 5032059 | Immune response |
| IGF-binding protein 2 ( | 498 | −0.28 (−0.44, −0.12) | 0.14 | 0.0495 | 55925576 | IGF binding |
Ten proteins quantified by MS and estimated by linear mixed-effects modeling in >10% of the samples that were positively and negatively associated with HAZ (q < 0.05), listed by the direction and strength of association (in increasing order of q). HAZ, height-for-age z score; IGF, insulin-like growth factor.
Number of child plasma samples in which each protein was detected and quantified by MS. HAZ outliers (n = 2) were excluded; thus, the maximum number was 498.
Estimated change in HAZ (95% CI) of children per 50% (1.5 times) increase in the relative abundance of a protein.
Proportion of variability in HAZ explained by protein.
Multiple hypothesis testing was corrected by using the false discovery rate.
GenInfo sequence number as assigned to all protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, NIH (35).
Represented or known molecular function or biological process of protein.
FIGURE 2Heatmap of plasma proteins associated with HAZ in 6- to 8-y-old Nepalese children (q < 0.05). Each row and column denotes protein and individual child, respectively. Children (n = 498) were ordered by their HAZ in increasing order from the left to right side. The color of each cell indicates linear mixed-effects model–estimated relative abundance of protein. Blue and red indicate high and low abundance relative to the mean value of each protein, respectively. Row dendrogram (on the left side of heatmap) shows a hierarchical clustering of proteins based on their correlations. The shorter horizontal subbranches represent the higher correlations. AFM, afamin; APOL1, apolipoprotein L1; CLEC3B, tetranectin; CNDP1, carnosinase 1; HAZ, height-for-age z score; IGFALS, insulin-like growth factor, acid labile subunit; IGFBP, insulin-like growth factor–binding protein; IGF1, insulin-like growth factor I; S100A12, protein S100-A12; VASN, vasorin.
Plasma proteins associated with AMA in 6- to 8-y-old Nepalese children (q < 0.05)
| Protein (gene symbol) | Change in AMA | Accession | Molecular function or biological process | |||
| Positive associations | ||||||
| IGF-binding protein, acid labile subunit ( | 499 | 1.03 (0.64, 1.42) | 0.05 | 1.00 × 10−4 | 4826772 | IGF binding |
| IGF-binding protein 3 ( | 499 | 0.82 (0.45, 1.18) | 0.04 | 0.0043 | 62243068 | IGF binding |
| CD93 antigen ( | 415 | 0.86 (0.42, 1.3) | 0.03 | 0.0238 | 88758613 | Cell adhesion |
| Collagen VI, α1 ( | 471 | 0.89 (0.43, 1.34) | 0.03 | 0.0238 | 87196339 | ECM of skeletal muscle |
| Endoglin ( | 430 | 0.89 (0.42, 1.36) | 0.03 | 0.0238 | 4557555 | Regulation of ECM synthesis |
| Pigment epithelium-derived factor ( | 499 | 1.23 (0.57, 1.88) | 0.03 | 0.0238 | 39725934 | Anti-angiogenesis |
| Anthrax toxin receptor 1 ( | 338 | 0.80 (0.37, 1.23) | 0.04 | 0.0238 | 14149904 | ECM homeostasis |
| Fibroblast activation protein ( | 422 | 0.77 (0.35, 1.19) | 0.03 | 0.0239 | 16933540 | ECM remodeling |
| Chemokine (C-C motif) ligand 14 ( | 77 | 1.66 (0.7, 2.61) | 0.17 | 0.0369 | 14589961 | Intracellular Ca2+ regulation |
| Complement factor D ( | 499 | 1.24 (0.52, 1.96) | 0.02 | 0.0404 | 42544239 | Complement activation or insulin regulation |
| IGF I ( | 173 | 0.66 (0.27, 1.06) | 0.06 | 0.046 | 163659901 | Growth factor |
| Threonine synthase–like 1 ( | 166 | 0.96 (0.38, 1.54) | 0.06 | 0.046 | 153792148 | Amino acid biosynthesis |
| Cartilage oligomeric matrix protein ( | 499 | 0.65 (0.26, 1.04) | 0.02 | 0.046 | 40217843 | ECM (noncollagenous glycoprotein) |
| Perlecan ( | 492 | 1.26 (0.5, 2.02) | 0.02 | 0.046 | 126012571 | ECM (proteoglycan) |
| Carnosinase 1 ( | 499 | 0.39 (0.15, 0.62) | 0.02 | 0.046 | 21071039 | Carnosine hydrolase |
| Negative associations | ||||||
| Heparin cofactor II ( | 499 | −0.99 (−1.53, −0.46) | 0.03 | 0.0238 | 73858566 | Thrombin inhibitor |
| Phosphogluconate dehydrogenase ( | 97 | −1.05 (−1.66, −0.44) | 0.28 | 0.0369 | 40068518 | Enzyme in the pentose phosphate pathway |
Seventeen proteins quantified by MS and estimated by linear mixed-effects modeling in >10% of the samples that were positively and negatively associated with AMA (q < 0.05), listed by the direction and strength of association (in increasing order of q). AMA, arm muscle area; ECM, extracellular matrix; IGF, insulin-like growth factor.
Number of child plasma samples in which each protein was detected and quantified by MS. One outlier of AMA was excluded; thus, the maximum number of children included in the analysis was 499.
Estimated change in AMA (in square centimeters) (95% CI) of children per 50% (1.5 times) increase in the relative abundance of protein.
Proportion of variability in AMA explained by protein.
Multiple hypothesis testing was corrected by using the false discovery rate.
GenInfo sequence number as assigned to all protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, NIH (35).
Represented or known molecular function or biological process of protein.
FIGURE 3Matrix of correlation coefficients among plasma proteins associated with arm muscle area in 6- to 8-y-old Nepalese children (q < 0.05). Blue and red indicate positive and negative correlations, respectively, and darker colors represent a stronger association. All correlation coefficients (r) are presented as r × 102 to improve visualization. Proteins with sample size <100 (n = 2) were not included. ANTXR1, anthrax toxin receptor 1; CD93, CD93 antigen; CFD, complement factor D; CNDP1, carnosinase 1; COL6A1, collagen VI, α1; COMP, cartilage oligomeric matrix protein; ENG, endoglin; FAP, fibroblast activation protein; HCF2, heparin cofactor II; HSPG2, perlecan; IGFALS, insulin-like growth factor, acid labile subunit; IGFBP3, insulin like-growth factor–binding protein 3; IGF1, insulin-like growth factor I; PEDF, pigment epithelium-derived factor; THNSL1, threonine synthase–like 1.
Plasma proteins positively and negatively associated with WAZ in 6- to 8-y-old Nepalese children (q < 0.05)
| Protein (gene symbol) | Change in WAZ | Accession | Molecular function or biological process | |||
| Positive associations | ||||||
| IGF-binding protein, acid labile subunit ( | 499 | 0.74 (0.6, 0.89) | 0.26 | 6.59 × 10−21 | 4826772 | IGF binding |
| IGF-binding protein 3 ( | 499 | 0.57 (0.43, 0.71) | 0.20 | 3.80 × 10−13 | 62243068 | IGF binding |
| IGF I ( | 173 | 0.37 (0.23, 0.51) | 0.17 | 5.13 × 10−05 | 163659901 | Growth factor |
| Carnosinase 1 ( | 499 | 0.21 (0.12, 0.31) | 0.11 | 0.0011 | 21071039 | Carnosine hydrolase |
| Pigment epithelium-derived factor ( | 499 | 0.58 (0.32, 0.84) | 0.11 | 0.0021 | 39725934 | Anti-angiogenesis |
| Perlecan ( | 492 | 0.58 (0.28, 0.89) | 0.10 | 0.0133 | 126012571 | ECM (proteoglycan) |
| Noelin ( | 464 | 0.44 (0.21, 0.67) | 0.12 | 0.0142 | 17136143 | Neural development |
| Afamin ( | 499 | 0.36 (0.16, 0.56) | 0.10 | 0.0166 | 4501987 | Vitamin E transport |
| Attractin ( | 499 | 0.51 (0.23, 0.79) | 0.10 | 0.0166 | 21450863 | Inflammatory response |
| Anthrax toxin receptor 1 ( | 338 | 0.31 (0.14, 0.47) | 0.08 | 0.0166 | 14149904 | ECM homeostasis |
| Collagen VI, α1 ( | 471 | 0.32 (0.14, 0.51) | 0.11 | 0.0259 | 87196339 | ECM of skeletal muscle |
| Neuropilin 1 ( | 457 | 0.31 (0.13, 0.49) | 0.13 | 0.0265 | 66864913 | Angiogenesis |
| Complement factor D ( | 499 | 0.5 (0.21, 0.79) | 0.10 | 0.0265 | 42544239 | Complement activation or adipokine |
| Endoglin ( | 430 | 0.32 (0.13, 0.51) | 0.04 | 0.0290 | 4557555 | Regulation of ECM synthesis |
| Apolipoprotein L1 ( | 499 | 0.28 (0.12, 0.45) | 0.10 | 0.0290 | 211938442 | Lipid transport |
| Thrombospondin 4 ( | 451 | 0.24 (0.1, 0.37) | 0.08 | 0.0290 | 31543806 | ECM (noncollagenous glycoprotein) |
| Chemokine (C-C motif) ligand 14 ( | 77 | 0.65 (0.26, 1.05) | 0.13 | 0.0349 | 14589961 | Intracellular Ca2+ regulation |
| Fibroblast activation protein, α subunit ( | 422 | 0.28 (0.11, 0.45) | 0.06 | 0.0354 | 16933540 | ECM remodeling |
| Cadherin 5 ( | 499 | 0.34 (0.13, 0.55) | 0.10 | 0.0424 | 166362713 | Endothelial cell-cell adhesion |
| Collagen VI, α3 ( | 471 | 0.35 (0.13, 0.56) | 0.12 | 0.0424 | 55743106 | ECM of skeletal muscle |
| Tetranectin ( | 499 | 0.43 (0.16, 0.71) | 0.10 | 0.0465 | 156627579 | Bone matrix |
| Mannan-binding lectin serine protease 2 ( | 112 | 0.67 (0.23, 1.1) | 0.24 | 0.0465 | 21264363 | Complement activation |
| Negative associations | ||||||
| Protein S100-A12 ( | 376 | −0.21 (−0.31, −0.1) | 0.06 | 0.0077 | 5032059 | Immune response |
| Myosin light-chain kinase, smooth muscle ( | 74 | −0.96 (−1.44, −0.48) | 0.18 | 0.0077 | 116008190 | Muscle contraction |
| Adipocyte plasma membrane–associated protein ( | 485 | −0.28 (−0.43, −0.14) | 0.06 | 0.0133 | 24308201 | Adipocyte differentiation |
| IGF-binding protein 2 ( | 499 | −0.28 (−0.44, −0.13) | 0.10 | 0.0166 | 55925576 | IGF binding |
| Chromogranin A ( | 339 | −0.27 (−0.43, −0.11) | 0.08 | 0.0354 | 4502805 | Neuroendocrine secretory protein |
| Thioredoxin ( | 311 | −0.25 (−0.41, −0.1) | 0.07 | 0.0405 | 50592994 | Redox homeostasis |
| Platelet glycoprotein V ( | 445 | −0.24 (−0.39, −0.09) | 0.07 | 0.0424 | 4758460 | Platelet aggregation |
| Stonin-2 ( | 125 | −0.34 (−0.55, −0.12) | 0.09 | 0.0445 | 21361863 | Endocytosis |
| Phosphogluconate dehydrogenase ( | 97 | −0.44 (−0.73, −0.16) | 0.17 | 0.0465 | 40068518 | Enzyme in the pentose phosphate pathway |
| Cathepsin D ( | 307 | −0.23 (−0.37, −0.08) | 0.13 | 0.0465 | 4503143 | Lysosomal protease |
| Hemopexin ( | 499 | −0.48 (−0.79, −0.17) | 0.10 | 0.0491 | 11321561 | Heme transport |
Thirty-three proteins quantified by MS and estimated by linear mixed-effects modeling in >10% of the samples that were positively and negatively associated with WAZ (q < 0.05), listed by the direction and strength of association (in increasing order of q). ECM, extracellular matrix; IGF, insulin-like growth factor; WAZ, weight-for-age z score.
Number of child plasma samples in which each protein was detected and quantified by MS. One outlier of WAZ was excluded; thus, the maximum number of children included in the analysis was 499.
Estimated change in WAZ (95% CI) of children per 50% (1.5 times) increase in the relative abundance of protein.
Proportion of variability in WAZ explained by protein.
Multiple hypothesis testing was corrected by using false discovery rate.
GenInfo sequence number as assigned to all protein sequences by the National Center for Biotechnology Information at the National Library of Medicine, NIH (35).
Represented or known molecular function or biological process of protein.